Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia

Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2007
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23720
Acceso en línea:
https://repository.urosario.edu.co/handle/10336/23720
Palabra clave:
Hepatitis B antibody
Hepavax
Recombinant hepatitis B vaccine
Unclassified drug
Adult
Age distribution
Article
Cigarette smoking
Colombia
Dose time effect relation
Drug dose comparison
Drug efficacy
Enzyme linked immunosorbent assay
Female
Health care personnel
Hepatitis B
Human
Immunogenicity
Major clinical study
Male
Multivariate analysis
Occupational health
Prevalence
Sex difference
Hepatitis B
Immunogenicity
Vaccination
Rights
License
Abierto (Texto Completo)
id EDOCUR2_aed031862ee0e3cae567dd42dcef55b7
oai_identifier_str oai:repository.urosario.edu.co:10336/23720
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 55ba803e-3d54-45e9-92b3-bfb362dc0294-1794573976002020-05-26T00:04:48Z2020-05-26T00:04:48Z2007Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using the ELISA technique during December 2000 and January 2001, taking into account that the last dose in the vaccination varied between 1 and 6 years. Results: A total of 344 men and 259 women with an age mean of 38.8±7.3 years were studied. Protection levels were found in 90.7% (?10 U/1), decreasing significantly with the worker's age (p less than 0.00 1) and with the vaccine last dose administration time (p less than 0.01). Health workers with four doses compared to those with three doses had a 4.7% higher protection (antibody median 209.8 vs. 130.07, p less than 0.001). No association was found with gender (p=0.463), smoking (p=0.331) and blood exposure (p=0.433). Multivariate analyses found that no protection associated only with age (40-44 years HR=2.37, Cl 95%:1.18,4.78 and ?45 years HR=3.58, Cl 95%: 1.83,6.99). Conclusions: Although Hepavax-Gene recombinant hepatitis B vaccine (anti-HBs) has a high effectiveness in the health workers (90.7%) it presents a decrease in protection levels related to a higher worker's age and along vaccine last dose administration time. © 2007 Corporación Editora Médica del Valle.application/pdf1657953401208322https://repository.urosario.edu.co/handle/10336/23720engUniversidad del Valle-Facultad de Salud381No. 4375Colombia MedicaVol. 38Colombia Medica, ISSN:16579534, 01208322, Vol.38, No.4 (2007); pp. 375-381https://www.scopus.com/inward/record.uri?eid=2-s2.0-38349068912&partnerID=40&md5=4aa33def3e6d4a2d6537b38eb73ce849Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURHepatitis B antibodyHepavaxRecombinant hepatitis B vaccineUnclassified drugAdultAge distributionArticleCigarette smokingColombiaDose time effect relationDrug dose comparisonDrug efficacyEnzyme linked immunosorbent assayFemaleHealth care personnelHepatitis BHumanImmunogenicityMajor clinical studyMaleMultivariate analysisOccupational healthPrevalenceSex differenceHepatitis BImmunogenicityVaccinationImmunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, ColombiaImmunogenicidad de una vacuna recombinante anti-HBs en trabajadores de la salud, del instituto de Medicina Legal de ColombiaarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Siachoque H.Ibáñez Pinilla, MilcíadesORIGINAL522-Manuscript-1578-1-10-20091125.pdfapplication/pdf258390https://repository.urosario.edu.co/bitstreams/e9dd0da1-2a6b-41fb-8f1e-48c4e814063c/download8483f541b3ef6465de9575b29d9bbf53MD51TEXT522-Manuscript-1578-1-10-20091125.pdf.txt522-Manuscript-1578-1-10-20091125.pdf.txtExtracted texttext/plain26965https://repository.urosario.edu.co/bitstreams/c26780be-a94f-477b-a2d0-1f70be0b161f/download130fae094b2cc836cb3a00d4ac3da413MD52THUMBNAIL522-Manuscript-1578-1-10-20091125.pdf.jpg522-Manuscript-1578-1-10-20091125.pdf.jpgGenerated Thumbnailimage/jpeg4287https://repository.urosario.edu.co/bitstreams/d7fbcfb2-0ae5-4df9-b612-0739c8fe1902/download471e6cfd57a444f498e8d4b1b647005dMD5310336/23720oai:repository.urosario.edu.co:10336/237202022-05-02 07:37:21.208365https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia
dc.title.TranslatedTitle.spa.fl_str_mv Immunogenicidad de una vacuna recombinante anti-HBs en trabajadores de la salud, del instituto de Medicina Legal de Colombia
title Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia
spellingShingle Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia
Hepatitis B antibody
Hepavax
Recombinant hepatitis B vaccine
Unclassified drug
Adult
Age distribution
Article
Cigarette smoking
Colombia
Dose time effect relation
Drug dose comparison
Drug efficacy
Enzyme linked immunosorbent assay
Female
Health care personnel
Hepatitis B
Human
Immunogenicity
Major clinical study
Male
Multivariate analysis
Occupational health
Prevalence
Sex difference
Hepatitis B
Immunogenicity
Vaccination
title_short Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia
title_full Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia
title_fullStr Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia
title_full_unstemmed Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia
title_sort Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia
dc.subject.keyword.spa.fl_str_mv Hepatitis B antibody
Hepavax
Recombinant hepatitis B vaccine
Unclassified drug
Adult
Age distribution
Article
Cigarette smoking
Colombia
Dose time effect relation
Drug dose comparison
Drug efficacy
Enzyme linked immunosorbent assay
Female
Health care personnel
Hepatitis B
Human
Immunogenicity
Major clinical study
Male
Multivariate analysis
Occupational health
Prevalence
Sex difference
Hepatitis B
Immunogenicity
Vaccination
topic Hepatitis B antibody
Hepavax
Recombinant hepatitis B vaccine
Unclassified drug
Adult
Age distribution
Article
Cigarette smoking
Colombia
Dose time effect relation
Drug dose comparison
Drug efficacy
Enzyme linked immunosorbent assay
Female
Health care personnel
Hepatitis B
Human
Immunogenicity
Major clinical study
Male
Multivariate analysis
Occupational health
Prevalence
Sex difference
Hepatitis B
Immunogenicity
Vaccination
description Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using the ELISA technique during December 2000 and January 2001, taking into account that the last dose in the vaccination varied between 1 and 6 years. Results: A total of 344 men and 259 women with an age mean of 38.8±7.3 years were studied. Protection levels were found in 90.7% (?10 U/1), decreasing significantly with the worker's age (p less than 0.00 1) and with the vaccine last dose administration time (p less than 0.01). Health workers with four doses compared to those with three doses had a 4.7% higher protection (antibody median 209.8 vs. 130.07, p less than 0.001). No association was found with gender (p=0.463), smoking (p=0.331) and blood exposure (p=0.433). Multivariate analyses found that no protection associated only with age (40-44 years HR=2.37, Cl 95%:1.18,4.78 and ?45 years HR=3.58, Cl 95%: 1.83,6.99). Conclusions: Although Hepavax-Gene recombinant hepatitis B vaccine (anti-HBs) has a high effectiveness in the health workers (90.7%) it presents a decrease in protection levels related to a higher worker's age and along vaccine last dose administration time. © 2007 Corporación Editora Médica del Valle.
publishDate 2007
dc.date.created.spa.fl_str_mv 2007
dc.date.accessioned.none.fl_str_mv 2020-05-26T00:04:48Z
dc.date.available.none.fl_str_mv 2020-05-26T00:04:48Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.issn.none.fl_str_mv 16579534
01208322
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/23720
identifier_str_mv 16579534
01208322
url https://repository.urosario.edu.co/handle/10336/23720
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 381
dc.relation.citationIssue.none.fl_str_mv No. 4
dc.relation.citationStartPage.none.fl_str_mv 375
dc.relation.citationTitle.none.fl_str_mv Colombia Medica
dc.relation.citationVolume.none.fl_str_mv Vol. 38
dc.relation.ispartof.spa.fl_str_mv Colombia Medica, ISSN:16579534, 01208322, Vol.38, No.4 (2007); pp. 375-381
dc.relation.uri.spa.fl_str_mv https://www.scopus.com/inward/record.uri?eid=2-s2.0-38349068912&partnerID=40&md5=4aa33def3e6d4a2d6537b38eb73ce849
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Universidad del Valle-Facultad de Salud
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
bitstream.url.fl_str_mv https://repository.urosario.edu.co/bitstreams/e9dd0da1-2a6b-41fb-8f1e-48c4e814063c/download
https://repository.urosario.edu.co/bitstreams/c26780be-a94f-477b-a2d0-1f70be0b161f/download
https://repository.urosario.edu.co/bitstreams/d7fbcfb2-0ae5-4df9-b612-0739c8fe1902/download
bitstream.checksum.fl_str_mv 8483f541b3ef6465de9575b29d9bbf53
130fae094b2cc836cb3a00d4ac3da413
471e6cfd57a444f498e8d4b1b647005d
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1818106608193896448